Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced its participation in the 45th Annual TD Cowen Healthcare Conference scheduled for March 3-5, 2025, in Boston, MA.
The company will provide a live audio webcast of their presentation, which will be accessible through the 'Investors' section of Xenon's website, with a replay option available post-event.
Xenon specializes in developing ion channel products targeting epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its fourth quarter 2024 financial results after U.S. market close on Thursday, February 27, 2025. The company will host a conference call and webcast, which will be available on the 'Investors' section of Xenon's website with a replay option following the event.
The company is advancing an ion channel product portfolio focused on epilepsy and depression. Their lead candidate, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (XENE) has outlined significant milestones for 2025, highlighting progress in its pipeline programs. The company anticipates topline data from its first Phase 3 FOS study in H2 2025, marking a important step toward NDA filing for azetukalner. The company has initiated the first of three planned Phase 3 MDD studies and is advancing its ion channel portfolio.
Key developments include continued advancement of Phase 3 azetukalner clinical studies in focal onset seizures, with over 600 patient-years of data from the ongoing X-TOLE open-label extension study. The Phase 3 X-ACKT study for primary generalized tonic-clonic seizures (PGTCS) continues enrollment. Additionally, Xenon has launched X-NOVA2, the first of three Phase 3 trials for Major Depressive Disorder (MDD), with topline results from a Mount Sinai investigator-led study expected in H1 2025.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, scheduled for January 13-16, 2025. The company's presentation will be delivered by Ian Mortimer, President and CEO, on Monday, January 13, 2025, from 9:45-10:25 AM Pacific Time.
As a neuroscience-focused biopharmaceutical company, Xenon is dedicated to developing therapeutics for areas of high unmet medical need, particularly in epilepsy and depression. Their leading product, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
The presentation will be accessible via live audio webcast through the 'Investors' section of Xenon's website, with a replay available after the event. The company focuses on advancing an ion channel product portfolio, emphasizing their commitment to discovering and delivering life-changing treatments for patients.
Xenon Pharmaceuticals presented new long-term data from its X-TOLE open-label extension (OLE) study of azetukalner for focal onset seizures at AES 2024. Key findings show that approximately one-third of patients on azetukalner for at least 36 months achieved seizure freedom for a year or longer, with sustained monthly seizure frequency reductions maintained at 85% at month 36.
The study demonstrated consistent tolerability and safety profile, with no new safety signals identified. Patient retention rates were 66%, 60%, and 52% at 12, 24, and 36 months respectively. Additional research presented highlighted significant mental health burdens in epilepsy patients and showed promising pre-clinical results for Nav1.1 potentiators in treating Dravet Syndrome.
Xenon Pharmaceuticals (XENE) announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2024), scheduled for December 6-10, 2024 in Los Angeles. The company will present five posters featuring new long-term 36-month data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS). The presentations will also cover mental health and comorbidity burdens of FOS, along with new pre-clinical data from the company's early-stage Nav1.1 program. The company will host a Scientific Exhibit and maintain booths at the event to showcase their clinical and research programs.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 18 at 9:10 a.m. ET and the Jefferies London Healthcare Conference 2024 on November 20 at 1:30 PM GMT / 8:30 am ET.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications. Webcasts of the presentations will be available on Xenon's website investor section.
Xenon Pharmaceuticals reported Q3 2024 financial results and provided updates on its clinical programs. The company's lead drug azetukalner, a Kv7 potassium channel opener, is advancing in Phase 3 trials for epilepsy with topline data expected in H2 2025. The company had $803.3 million in cash as of September 30, 2024, expecting to fund operations into 2027. Q3 net loss was $62.8 million, up from $48.5 million in Q3 2023, primarily due to increased R&D expenses. The company is expanding its pipeline with multiple candidates advancing towards IND filings in 2025, including programs for Kv7, Nav1.7, and Nav1.1 targets.
Xenon Pharmaceuticals (Nasdaq: XENE) has announced it will report its third quarter 2024 financial results after U.S. market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day. Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference on October 7, 2024. The company will present a fireside chat at 11:40 am Eastern Time, with a live webcast available on Xenon's website.
Xenon is dedicated to discovering, developing, and delivering life-changing therapeutics for patients with neurological and psychiatric disorders. Their novel product pipeline focuses on areas of high unmet medical need, including epilepsy and depression. The company's lead product, azetukalner, is a Kv7 channel opener in late-stage clinical development for multiple indications, representing the most advanced, clinically validated potassium channel modulator.